ACHIEVE LIFE SCIENCES, INC. Contracts & Agreements

Separation and Release Agreement, dated August 26, 2024, between Achieve Life Sciences, Inc. and John Bencich (Filed With SEC on November 7, 2024)

Executive Employment Agreement, dated August 26, 2024, between Achieve Life Sciences, Inc. and Thomas B. King (Filed With SEC on November 7, 2024)

Open Market Sale AgreementSM, dated September 27, 2024, between Achieve Life Sciences, Inc. and Jefferies LLC (Filed With SEC on September 27, 2024)

Contingent Convertible Debt Agreement, dated July 25, 2024, between Achieve Life Sciences, Inc., and Silicon Valley Bank, a division of First-Citizens Bank & Trust Company (Filed With SEC on July 29, 2024)

Registration Rights Agreement, dated July 25, 2024, between Achieve Life Sciences, Inc., and Silicon Valley Bank, a division of First-Citizens Bank & Trust Company (Filed With SEC on July 29, 2024)

Form of Indemnification Agreement for Officers and Directors of the Company (Filed With SEC on March 28, 2024)

Share Purchase Agreement, by and between Sopharma AD and Achieve Life Sciences, Inc., dated May 14, 2015 (Filed With SEC on March 28, 2024)

Office Lease by and between Regus Management Group, LLC and Achieve Life Sciences, Inc., commencing March 1, 2024 (Filed With SEC on March 28, 2024)

Form of Common Stock Warrant (Filed With SEC on February 29, 2024)

Securities Purchase Agreement, dated as of February 28, 2024, by and among Achieve Life Sciences, Inc. and the purchasers identified on the signature pages thereto (Filed With SEC on February 29, 2024)

Securities Purchase Agreement, dated as of May 25, 2023, by and among Achieve Life Sciences, Inc. and the purchasers identified on the signature pages thereto (Filed With SEC on May 25, 2023)

Amendment to the Cooperation Agreement, dated March 21, 2023, by and among Achieve Life Sciences, Inc., Dialectic Capital Management, LP and the other parties set forth on the... (Filed With SEC on March 23, 2023)

Achieve Life Sciences 2018 Equity Incentive Plan, as amended, and forms of award agreements thereunder (Filed With SEC on March 16, 2023)

Amendment to Office Lease, dated December 16, 2022, by and between 0846869 B.C. Ltd. and Achieve Life Sciences Technologies Inc (Filed With SEC on March 16, 2023)

Amended and Restated Employment Agreement, dated September 27, 2022, by and between Achieve Life Sciences, Inc. and Cindy Jacobs (Filed With SEC on March 16, 2023)

ACHIEVE LIFE SCIENCES, INC. 1040 West Georgia Street, Suite 1030 Vancouver, BC V6E 4H1 (Filed With SEC on March 6, 2023)

Form of Common Stock Purchase Warrant (Filed With SEC on November 18, 2022)

Form of Subscription Agreement (Filed With SEC on November 18, 2022)

Form of Registration Rights Agreement (Filed With SEC on November 18, 2022)

Loan and Security Agreement, dated April 26, 2022, among Achieve Life Sciences, Inc. and Silicon Valley Bank (Filed With SEC on April 27, 2022)

First Amendment to 2021 Contingent Convertible Debt Agreement dated December 22, 2021 by and among Achieve Life Sciences, Inc., Silicon Valley Bank, and SVB Innovation Credit Fund... (Filed With SEC on April 27, 2022)

Contingent Convertible Debt Agreement, dated December 22, 2021, among Achieve Life Sciences, Inc., Silicon Valley Bank and SVB Innovation Credit Fund VIII, L.P (Filed With SEC on December 22, 2021)

Registration Rights Agreement, dated December 22, 2021, among Achieve Life Sciences, Inc., Silicon Valley Bank and SVB Innovation Credit Fund VIII, L.P (Filed With SEC on December 22, 2021)

Underwriting Agreement dated May 25, 2021 (Filed With SEC on May 25, 2021)

Form of Underwriting Agreement (Filed With SEC on November 30, 2020)

Form of Underwriters Warrant (Filed With SEC on November 30, 2020)

Letter of Variation, dated September 28, 2020, by and between Achieve Pharma UK Limited and Richard Stewart (Filed With SEC on November 12, 2020)

Letter of Variation, dated September 28, 2020, by and between Achieve Pharma UK Limited and Anthony Clarke (Filed With SEC on November 12, 2020)

Amended and Restated Employment Agreement, dated September 28, 2020, by and between Achieve Life Sciences, Inc. and John Bencich (Filed With SEC on November 12, 2020)

Amended and Restated Employment Agreement, dated September 28, 2020, by and between Achieve Life Sciences, Inc. and Cindy Jacobs (Filed With SEC on November 12, 2020)

Underwriting Agreement dated August 3, 2020 (Filed With SEC on August 5, 2020)

Form of Pre-Funded Warrant (Filed With SEC on August 5, 2020)

Form of Common Stock Purchase Warrant (Filed With SEC on April 30, 2020)

Placement Agent Agreement dated as of April 19, 2020, by and between Achieve Life Sciences, Inc. and Paulson Investment Company, LLC (Filed With SEC on April 30, 2020)

Form of Subscription Agreement (Filed With SEC on April 30, 2020)

Form of Registration Rights Agreement (Filed With SEC on April 30, 2020)

Description of Securities Registered Under Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on March 13, 2020)

Amendment No. 1 to Purchase Agreement, by and between Achieve Life Sciences, Inc. and Lincoln Park Capital Fund, LLC. dated as of September 14, 2017 (Filed With SEC on March 13, 2020)

Form of Common Stock Purchase Warrant (Filed With SEC on December 20, 2019)

Form of Preferred Stock Certificate (Filed With SEC on December 20, 2019)

Underwriting Agreement dated as of December 17, 2019, by and between Achieve Life Sciences, Inc. and Ladenburg Thalmann & Co. Inc (Filed With SEC on December 20, 2019)

Form of Warrant Offered Hereby (Filed With SEC on December 16, 2019)

Form of Leak-out Agreement (Filed With SEC on December 16, 2019)

Form of Underwriting Agreement (Filed With SEC on December 16, 2019)

Form of Underwriting Agreement (Filed With SEC on December 2, 2019)

Form of Indemnification Agreement for Officers and Directors of the Company (Filed With SEC on November 6, 2019)

At The Market Offering Agreement, dated June 7, 2019, by and between Achieve Life Sciences, Inc. and H.C. Wainwright & Co., LLC (Filed With SEC on June 7, 2019)

Common Stock Purchase Warrant, dated as of May 30, 2019 (Filed With SEC on June 3, 2019)

Warrant Exercise Agreement, dated as of May 30, 2019, by and between Achieve Life Sciences, Inc. and Armistice Capital Master Fund, Ltd (Filed With SEC on June 3, 2019)

Office Lease by and between 0846869 B.C. Ltd. and Achieve Life Sciences Technologies Inc., commencing February 1, 2019 (Filed With SEC on March 14, 2019)

ACHIEVE LIFE SCIENCES, INC. 2018 EQUITY INCENTIVE PLAN (Filed With SEC on November 7, 2018)

Placement Agency Agreement, dated as of October 1, 2018, by and between Achieve Life Sciences, Inc. and Ladenburg Thalmann & Co. Inc (Filed With SEC on October 1, 2018)

Form of Warrant (Filed With SEC on October 1, 2018)

Securities Purchase Agreement, dated as of October 1, 2018, by and among Achieve Life Sciences, Inc. and the purchasers identified on the signature pages thereto (Filed With SEC on October 1, 2018)

Underwriting Agreement dated as of June 15, 2018, by and between Achieve Life Sciences, Inc. and Ladenburg Thalmann & Co. Inc (Filed With SEC on June 20, 2018)

Form of Common Stock Purchase Warrant (Filed With SEC on June 20, 2018)

Form of Preferred Stock Certificate (Filed With SEC on June 20, 2018)

Employment Agreement between the Company and Richard Stewart, executed May 22, 2018 (Filed With SEC on May 23, 2018)

Employment Agreement between the Company and Anthony Clarke, executed May 22, 2018 (Filed With SEC on May 23, 2018)

Amendment to University of Bristol License Agreement, dated January 22, 2018, by and between Achieve Life Science, Inc., and the University of Bristol (Filed With SEC on May 9, 2018)

Form of Achieve Life Sciences Stock Option Agreement (Filed With SEC on March 1, 2018)

Form of Achieve Life Sciences Restricted Stock Unit Agreement (Filed With SEC on March 1, 2018)

Lease by and between 520 Pike Street, Inc. and Achieve Life Sciences, Inc., dated December 11, 2018 (Filed With SEC on March 1, 2018)

Amended and Restated Supply Agreement, dated July 28, 2017, by and between Achieve Life Science, Inc., and Sopharma AD (Filed With SEC on November 9, 2017)

Form of Warrant (Filed With SEC on September 14, 2017)

Purchase Agreement, dated as of September 14, 2017, by and between Achieve Life Sciences, Inc. and Lincoln Park Capital Fund, LLC (Filed With SEC on September 14, 2017)

SEPARATION AGREEMENT AND RELEASE (Filed With SEC on August 2, 2017)

AMENDMENT NO. 2 TO AGREEMENT AND PLAN OF MERGER AND REORGANIZATION (Filed With SEC on July 19, 2017)

AMENDMENT NO.1 TO AGREEMENT AND PLAN OF MERGER AND REORGANIZATION (Filed With SEC on May 15, 2017)

AGREEMENT AND PLAN OF MERGER AND REORGANIZATION by andamong: ONCOGENEX PHARMACEUTICALS, INC., a Delaware corporation; ASHACQUISITION SUB, INC., a Delaware corporation; ASH... (Filed With SEC on January 5, 2017)

SUPPORT AGREEMENT (Filed With SEC on January 5, 2017)

Lock-up Agreement (Filed With SEC on January 5, 2017)

CONTINGENT VALUE RIGHTS AGREEMENT (Filed With SEC on January 5, 2017)

Employment Agreement (Filed With SEC on November 10, 2016)

ONCOGENEX PHARMACEUTICALS INC. SERIES A-1 WARRANT TO PURCHASE COMMON STOCK (Filed With SEC on April 30, 2015)

PURCHASE AGREEMENT (Filed With SEC on April 30, 2015)

AGREEMENT BETWEEN ONCOGENEX TECHNOLOGIES, INC. (OGX) AND TEVA PHARMACEUTICAL INDUSTRIES LTD. (Teva) (Filed With SEC on March 26, 2015)

Parklands North Creek OFFICE LEASE GrosvenorInternational (Atlantic Freeholds) Limited, a Nevada corporation and BBCAF-VRC, LLC, a Delaware limited liability company Landlord and... (Filed With SEC on February 12, 2015)

LEASE TERMINATION AGREEMENT (Filed With SEC on February 12, 2015)

EMPLOYMENT AGREEMENT (Filed With SEC on August 7, 2014)

OncoGenex Pharmaceuticals, Inc. 5,559,866 Shares Pre-Funded Warrants to Purchase 1,340,538 Shares Warrants to Purchase 3,450,202 Shares Common Stock ($0.001par value) Underwriting... (Filed With SEC on June 27, 2014)

ONCOGENEX PHARMACEUTICALS INC. SERIES A WARRANT TO PURCHASE COMMON STOCK (Filed With SEC on June 27, 2014)

ONCOGENEX PHARMACEUTICALS INC. PRE-FUNDED SERIES B WARRANT TO PURCHASECOMMON STOCK (Filed With SEC on June 27, 2014)

ONCOGENEX PHARMACEUTICALS INC. SERIES B WARRANT TO PURCHASE COMMON STOCK (Filed With SEC on June 27, 2014)

ONCOGENEX PHARMACEUTICALS, INC. Common Stock (par value $0.001 per share) At-the-Market Issuance Sales Agreement (Filed With SEC on June 18, 2013)

EMPLOYMENT AGREEMENT (Filed With SEC on February 4, 2013)

FULL & FINAL RELEASE (Filed With SEC on August 2, 2012)

OncoGenex Pharmaceuticals, Inc. 4,165,000 Shares Common Stock ($0.001 par value) Underwriting Agreement (Filed With SEC on March 16, 2012)

EX-101 INSTANCE DOCUMENT (Filed With SEC on November 3, 2011)

/s/ Scott Cormack Scott Cormack, President & CEO (Filed With SEC on November 8, 2010)

Employment Agreement (Filed With SEC on November 8, 2010)

OncoGenex Pharmaceuticals, Inc. (Filed With SEC on October 19, 2010)

ONCOGENEX PHARMACEUTICALS INC. Warrant To Purchase Common Stock (Filed With SEC on October 19, 2010)

ONCOGENEX PHARMACEUTICALS, INC. STOCK OPTION AGREEMENT (Filed With SEC on June 14, 2010)

ONCOGENEX PHARMACEUTICALS, INC. RESTRICTED STOCK PURCHASE AGREEMENT UNDER THE 2010 PERFORMANCE INCENTIVE PLAN (Filed With SEC on June 14, 2010)

OncoGenex Pharmaceuticals, Inc. Short Term Incentive Awards Program (Filed With SEC on June 14, 2010)

a phase 3 clinical trial of OGX-011 in approximately 300 patients with second-line castrate resistant prostate cancer (CRPC), expected to initiate in the second quater of 2010... (Filed With SEC on March 8, 2010)

EMPLOYMENT AGREEMENT (Filed With SEC on March 1, 2010)

EMPLOYMENT AMENDING AGREEMENT (Filed With SEC on March 1, 2010)

OncoGenexTechnologies Inc. is a wholly owned subsidiary of OncoGenexPharmaceuticals, Inc. NASD- OGXI www.oncogenex.com (Filed With SEC on February 25, 2010)

Consolidated Financial Statements (Filed With SEC on November 5, 2009)

SUBSCRIPTION AGREEMENT (Filed With SEC on July 20, 2009)

OncoGenex Pharmaceuticals, Inc. Short Term Incentive Awards Program (Filed With SEC on April 2, 2009)

Agreement and Consent Form (Filed With SEC on April 2, 2009)

longer survival duration when adding OGX-011 to first-line docetaxel compared to first-line docetaxel alone in patients with CRPC within a randomized phase 2 trial (Filed With SEC on March 11, 2009)

FIRST AMENDMENT TO ARRANGEMENT AGREEMENT (Filed With SEC on November 10, 2008)

SECOND AMENDMENT TO ARRANGEMENT AGREEMENT (Filed With SEC on November 10, 2008)

EXECUTIVE TERMINATION AGREEMENT AND GENERAL RELEASE (Filed With SEC on November 10, 2008)

EMPLOYMENT AMENDING AGREEMENT (Filed With SEC on November 10, 2008)

AMENDED AND RESTATED LICENSE AGREEMENT (Filed With SEC on November 10, 2008)

SECOND AMENDING AGREEMENT AND CONSENT (Filed With SEC on November 10, 2008)

SECOND AMENDING AGREEMENT (Filed With SEC on November 10, 2008)

THIRDAMENDMENT TO AMENDED AND RESTATED RIGHTS AGREEMENT (Filed With SEC on May 30, 2008)

VOTING AGREEMENT (Filed With SEC on May 30, 2008)

SCHEDULE OF PARTIES TO ONCOGENEX VOTING AGREEMENTS (Filed With SEC on May 30, 2008)

VOTING AGREEMENT (Filed With SEC on May 30, 2008)

SCHEDULE OF PARTIES TO SONUS VOTING AGREEMENTS (Filed With SEC on May 30, 2008)

SECONDAMENDMENT TO LEASE (Filed With SEC on May 9, 2008)

FIRST AMENDMENT TO LEASE (Filed With SEC on March 14, 2008)

SONUS PHARMACEUTICALS, INC. 1522 217th PL S.E., Suite 100 Bothell, Washington 98021 January 11, 2008 (Filed With SEC on January 17, 2008)

SONUS PHARMACEUTICALS, INC. RESTRICTED STOCK PURCHASEAGREEMENT UNDER THE 2007 PERFORMANCE INCENTIVE PLAN (Filed With SEC on November 9, 2007)

SONUS PHARMACEUTICALS, INC. STOCK OPTION AGREEMENT (Filed With SEC on November 9, 2007)

LEASE by and between BMR-217THPLACE LLC, a Delaware limitedliability company and SONUS PHARMACEUTICALS,INC. a Delawarecorporation (Filed With SEC on March 16, 2007)

CLINICAL SUPPLY AGREEMENT (Filed With SEC on March 16, 2007)

SonusPharmaceuticals, Inc. CompensationPolicy (Filed With SEC on December 15, 2006)

SonusPharmaceuticals, Inc. ExecutiveCompensation Program (Filed With SEC on December 15, 2006)

FIRST AMENDMENT TO SONUS PHARMACEUTICALS, INC. 2000 STOCK INCENTIVE PLAN (Filed With SEC on November 8, 2006)

6,130,000 Shares SONUS PHARMACEUTICALS, INC. Common Stock PLACEMENT AGENCY AGREEMENT (Filed With SEC on May 1, 2006)

PURCHASE AGREEMENT (Filed With SEC on May 1, 2006)

COLLABORATIONAND LICENSE AGREEMENT between SONUSPHARMACEUTICALS, INC. and SCHERINGAG Dated: October 17th2005 (Filed With SEC on March 16, 2006)

SECURITIES PURCHASE AGREEMENT (Filed With SEC on March 16, 2006)

REGISTRATIONRIGHTS AGREEMENT (Filed With SEC on March 16, 2006)

SECURITIES PURCHASE AGREEMENT (Filed With SEC on August 18, 2005)

REGISTRATION RIGHTS AGREEMENT (Filed With SEC on August 18, 2005)

PURCHASE WARRANT Issued to: Exercisable to Purchase ________ Shares of Common Stock of SONUS PHARMACEUTICALS, INC. Void after August 15, 2010 (Filed With SEC on August 18, 2005)

Amendedand Restated Sonus Pharmaceuticals, Inc. ExecutiveCompensation Program (Filed With SEC on January 4, 2005)

SONUS PHARMACEUTICALS, INC. SHORT-TERM INCENTIVE PROGRAM PERFORMANCE AWARD (Filed With SEC on January 4, 2005)

AMENDED AND RESTATED STOCK PURCHASE AGREEMENT by and among SONUS PHARMACEUTICALS, INC. and SELLERS MANAGERS COMPANY OPTION HOLDERS COMPANY WARRANT HOLDERS and SELLERS AGENT Dated... (Filed With SEC on December 28, 2004)

EXHIBIT A FORM OF STOCKHOLDERS AGREEMENT (Filed With SEC on December 28, 2004)

Change in Control Agreement for Alan Fuhrman, dated September 15, 2004 (Filed With SEC on September 20, 2004)

Securities Purchase Agreement by and among the Company and the investors named therein, dated May 7, 2004 (Filed With SEC on May 13, 2004)

TOCOSOL Drug Delivery Technology (Filed With SEC on March 12, 2004)

Part I. Financial Information (Filed With SEC on August 13, 2003)

Not applicable (Filed With SEC on August 8, 2003)

Part I. Financial Information (Filed With SEC on August 13, 2002)

Technology Platform (Filed With SEC on March 5, 2002)

Financial Information (Filed With SEC on August 7, 2001)

Category

Industry

Companies

Contracts

ACHIEVE LIFE SCIENCES, INC. Contracts & Agreements